umu.sePublications
Change search
Link to record
Permanent link

Direct link
BETA
Westborg, Inger
Publications (10 of 11) Show all publications
Lövestam Adrian, M., Vassilev, Z. P. & Westborg, I. (2018). Baseline visual acuity as a prognostic factor for visual outcomes in patients treated with aflibercept for wet age-related macular degeneration: data from the INSIGHT study using the Swedish Macula Register. Acta Ophthalmologica
Open this publication in new window or tab >>Baseline visual acuity as a prognostic factor for visual outcomes in patients treated with aflibercept for wet age-related macular degeneration: data from the INSIGHT study using the Swedish Macula Register
2018 (English)In: Acta Ophthalmologica, ISSN 1755-375X, E-ISSN 1755-3768Article in journal (Refereed) Epub ahead of print
Abstract [en]

PURPOSE: To assess mean change in visual acuity (VA) overall and stratified by baseline VA after 1 and 2 years' treatment with aflibercept in a real-life setting.

METHODS: This was an observational cohort study using nationwide data from the Swedish Macula Register. Treatment-naïve patient eyes with wet age-related macular degeneration and prescribed aflibercept from January 2013 to December 2014 were followed for 1 year (2478 eyes) or 2 years (831 eyes) to assess VA. Eyes were grouped by baseline VA.

RESULTS: Mean number of injections in patients treated according to label (72%) versus patients treated not according to label was 8.0 ± 1.5 versus 4.4 ± 0.8 (p < 0.0001) at 1 year, and 12.5 ± 3.2 versus 7.3 ± 1.9 (p < 0.0001) at 2 years. Among all eyes, mean VA increased from 61.3 ± 13.4 Early Treatment Diabetic Retinopathy Study letters at baseline to 64.5 ± 15.6 at 1 year and 65.1 ± 15.1 letters at 2 years. At 2 years, eyes with good baseline vision (≥70 letters) lost a mean of 2.4 ± 11.3 to 72.3 letters, eyes with intermediate baseline VA (36-69 letters) gained 5.7 ± 14.1 to 62.7 letters, and eyes with poor baseline VA (≤35 letters) gained 13.2 ± 18.3 to 41.0 letters. Also at 2 years, 75% of treated eyes were stable or had improved VA. Among eyes with intermediate baseline VA, near vision was significantly better among those treated according to label versus not according to label at 3 (p = 0.019), 6 (p = 0.0002) and 12 months (p ≤ 0.0001).

CONCLUSION: While gain in vision was especially pronounced in eyes with poor baseline VA, good baseline VA was important for best prognosis.

Place, publisher, year, edition, pages
John Wiley & Sons, 2018
Keywords
aflibercept, age-related macular degeneration, neovascular AMD, prognosis, visual acuity, wet AMD
National Category
Ophthalmology
Identifiers
urn:nbn:se:umu:diva-152579 (URN)10.1111/aos.13864 (DOI)30238648 (PubMedID)
Available from: 2018-10-14 Created: 2018-10-14 Last updated: 2018-12-19
Westborg, I. & Rosso, A. (2018). Risk factors for discontinuation of treatment for neovascular age-related macular degeneration. Ophthalmic Epidemiology, 25(2), 176-182
Open this publication in new window or tab >>Risk factors for discontinuation of treatment for neovascular age-related macular degeneration
2018 (English)In: Ophthalmic Epidemiology, ISSN 0928-6586, E-ISSN 1744-5086, Vol. 25, no 2, p. 176-182Article in journal (Refereed) Published
Abstract [en]

Purpose: To investigate risk factors for treatment discontinuation for neovascular age-related macular degeneration (nAMD).

Methods: Data from the Swedish Macula Register and the Skane Healthcare Register are reported on the treatment received by 932 nAMD patients diagnosed 2013-2015. Treatment discontinuation is defined as having a termination visit or lacking a control or treatment visit during the period of 10-14months after the diagnostic visit. The risk of treatment discontinuation during the first year is estimated using a Poisson model and a classification tree.

Results: 503 eyes (50.9%) discontinued the treatment within the first year. Patients with visual acuity below 60 ETDRS letters (20/60 Snellen) at baseline, serious comorbidities, or treated at the university hospital have a 42% (95% CI 25-61%, P<0.001), 27% (95% CI 13-43%, P=0.001) and 30% (95% CI 15-46%, P<0.001) increased risk to discontinue treatment compared with similar patients. Patients on ranibizumab therapy have a 45% (95% CI 28-63%, P<0.001) increased risk for treatment discontinuation during year 1 compared with patients on aflibercept therapy. The classification tree also shows that patients on ranibizumab therapy and those with low VA at baseline are at a higher risk of terminating treatment.

Conclusions: Almost half of the patients starting anti-VEGF therapy discontinue treatment during the first year. Patients with risk factors may require additional support to continue with the treatment. Aflibercept therapy could be an alternative to patients at risk of treatment discontinuation.

Place, publisher, year, edition, pages
Taylor & Francis, 2018
Keywords
nAMD, machine learning, ranibizumab, aflibercept
National Category
Ophthalmology
Identifiers
urn:nbn:se:umu:diva-144853 (URN)10.1080/09286586.2017.1397701 (DOI)000423568000011 ()29131696 (PubMedID)
Available from: 2018-02-23 Created: 2018-02-23 Last updated: 2018-06-09Bibliographically approved
Westborg, I. & Rosso, A. (2018). Risk for low visual acuity after 1 and 2 years of treatment with anti-VEGF. Comparison of different agents: Ranibizumab, Aflibercept, and Bevacizumab. Paper presented at Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO), APR 29-MAY 03, 2018, Honolulu, HI. Investigative Ophthalmology and Visual Science, 59(9)
Open this publication in new window or tab >>Risk for low visual acuity after 1 and 2 years of treatment with anti-VEGF. Comparison of different agents: Ranibizumab, Aflibercept, and Bevacizumab
2018 (English)In: Investigative Ophthalmology and Visual Science, ISSN 0146-0404, E-ISSN 1552-5783, Vol. 59, no 9Article in journal, Meeting abstract (Other academic) Published
Abstract [en]

Purpose : To analyze the risk factors for low visual acuity and compare the visual acuity, number of visits and injections received by patients on different anti-vascular endothelial growth factor (anti-VEGF) therapies after one and two years of treatment.

Methods : Retrospective register-based cohort study from the national Swedish Macula Register (SMR). Treatment naïve eyes and treated exclusively with ranibizumab, bevacizumab or aflibercept, followed for two years. Evaluation of baseline characteristics as age, best corrected visual acuity (BCVA) and type of lesion and treatment drug. The risks of low visual acuity (BCVA ≤60 ETDRS letters) during the first and second year were estimated.

Results : Mean BCVA were 56.2, 62 and 62.5 ETDRS letters for baseline, year 1 and year 2 respectively. Aflibercept eyes received 5.9 injections year one and 3.9 year two. Bevacizumab and ranibizumab treated eyes received 5.3 and 4.7 injections year one and 3.8 and 3.1 injections year two respectively. The average number of vists in the ranibizumab and bevazicumab groups was slightly higher compared to aflibercept group both year 1 and 2. VA improved on average in all treatment groups. At year one 33% of eyes in Aflibercept and Bevacizumab and 34% in Ranibizumab treated group had a VA of less than 60 ETDRS letters. Number of eyes discontiuning treatment or lost to follow-up after two years were 55% (2016/3678). Low visual acuity were the main reason for discontinuation. Older patients and low baseline VA were risk factors for low VA after one and two years of treatment.

Conclusions : This study show a shift in treatment regimen in Sweden 2013 with increasing number of injections and an inclination to follow label with fewer visits and more injections instead of PRN (Pro re nata) regimen. Maintenance in mean VA after one and two years is seen in all treatment groups but eyes treated with aflibercept show a slightly better mean VA after one and two years. However, it is worth noticing that those patients have on average a better baseline VA. Treatment are also maintained in a higher degree for aflibercept treated eyes. Risk factors for low visual acuity after one and two years of treatment are, as expected, older patients and low baseline VA.

Place, publisher, year, edition, pages
The Association for Research in Vision and Ophthalmology, Inc., 2018
National Category
Ophthalmology
Identifiers
urn:nbn:se:umu:diva-152277 (URN)000442912502101 ()
Conference
Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO), APR 29-MAY 03, 2018, Honolulu, HI
Available from: 2018-10-02 Created: 2018-10-02 Last updated: 2018-10-02Bibliographically approved
Westborg, I. (2018). Safety and  efficacy in the cataract surgery process. (Doctoral dissertation). Umeå: Umeå Universitet
Open this publication in new window or tab >>Safety and  efficacy in the cataract surgery process
2018 (English)Doctoral thesis, comprehensive summary (Other academic)
Abstract [en]

Background

Cataract and age-related macular degeneration (AMD) are two major causes for visual impairment in the elderly. Cataract surgery is one of the most common surgical interventions performed in the western world. As a consequence of the increasing number of operations performed, postoperative visits are a large workload for surgical units. It is important that all parts of the cataract surgery procedure are appropriate and cost-effective. During the last 20 years the trend is towards fewer visits both pre- as well as postoperatively. The number and timing of postoperative visits are also a subject of an ongoing debate. Few studies have previously evaluated safety perspectives concerning the number and timing of post-operative visits.

The last decade, new treatments for wet AMD have evolved and the number of patients receiving treatment has increased. It has been debated if blue-blocking intraocular lenses (IOL) have a protective effect on the development of wet AMD and decreasing the need for AMD-treatment after cataract surgery.

Aims

To analyse parts of the modern cataract surgery process including peri- and post-operative routines from a safety and efficacy perspective. To analyse pre- and perioperative risk factors as well as protective factors associated with the need for wet AMD-treatment after cataract surgery.

Methods

I, II. These prospective, observational cohort studies included all cataract surgery cases (n=1249) during a 1-year period, at one institution. The cohort was analysed regarding the use of a standardized anaesthetic regimen and the safety perspectives, when the standard routine is no planned postoperative visit in uncomplicated cases without ocular comorbidity.

III. The above-mentioned cohort (study group), was compared with a cohort from another clinic (control group) with a different follow-up routine, i.e. each case with first eye cataract surgery had a planned postoperative visit. In the control group all patients (n= 1162 cases) had surgery during the same 1-year period. The number of planned and unplanned visits was recorded, and the surgical outcome from the two institutions was compared.

IV. A register-based cohort study included all patients registered in the Swedish National Cataract Register and the Swedish Macula Register in 2010 - 2017, to find all eyes with past cataract surgery that were subsequently treated for wet AMD. Complete registry data was used for comparisons and analyses of pre- and peri-operative risk- and protective factors for wet AMD treatment after cataract surgery.

Results

I. A standardized anaesthetic method with topical and intracameral anaesthetics without sedation was used in most cases (90%). Median pain score after surgery was 0.7 (VAS 0-10) and most patients (97%) would choose the same anaesthetic method again.

II, III. Evaluation of all medical records 2 years after the cataract surgery procedure, found no report of missed adverse events. Significantly less patients in the study group (9% vs 16%; p=0.000036) initiated a postoperative unplanned contact compared with the control group. Patients with 70 km or longer to the hospital were less inclined to seek unplanned care (p=0.016).

IV. Female gender and high age are associated with an increased risk of needing treatment for wet AMD ≥1 year after cataract surgery. Eyes with a diagnosis of AMD preoperatively, and subsequently treated for wet AMD, had a significantly (p=0.023) lower degree of blue-blocking IOLs implanted at their previous cataract surgery.

Conclusion

I. A standardized anaesthetic method with topical and intracameral anaesthetics without sedation seems well tolerated by the patients, and is effective at cataract surgery, also in cases when complications/adverse events occur.

II, III. Without compromising patient safety, it is possible to refrain from standard postoperative visits after cataract surgery in patients with uncomplicated surgery and no ocular comorbidity. A significant reduction in postoperative visits is only obtained if the standard routine applies to both first and second eye surgery.

IV. Patients without preoperative AMD have no benefit from the use of blue-blocking IOLs. In patients with preoperatively diagnosed AMD, blue-blocking IOLs may offer some protection from the subsequent development of AMD.

Place, publisher, year, edition, pages
Umeå: Umeå Universitet, 2018. p. 60
Series
Umeå University medical dissertations, ISSN 0346-6612 ; 1989
Keywords
Cataract, prospective cohort study, patient safety, age-related macular degeneration
National Category
Ophthalmology
Research subject
Ophtalmology
Identifiers
urn:nbn:se:umu:diva-152946 (URN)978-91-7601-955-9 (ISBN)
Public defence
2018-11-23, Hörsal D, Unod T9, plan 9 Tandläkarhögskolan, Norrlands Universitetssjukhus, Umeå, 09:00 (Swedish)
Opponent
Supervisors
Available from: 2018-11-02 Created: 2018-10-31 Last updated: 2018-11-08Bibliographically approved
Westborg, I. & Mönestam, E. (2017). Optimizing number of postoperative visits after cataract surgery: Safety perspective. Journal of cataract and refractive surgery, 43(9), 1184-1189
Open this publication in new window or tab >>Optimizing number of postoperative visits after cataract surgery: Safety perspective
2017 (English)In: Journal of cataract and refractive surgery, ISSN 0886-3350, E-ISSN 1873-4502, Vol. 43, no 9, p. 1184-1189Article in journal (Refereed) Published
Abstract [en]

Purpose: To evaluate safety perspectives when the standard routine after cataract surgery is no planned postoperative visit.

Setting: Eye Clinic, Sunderby Hospital, Lulea, Norrbotten County, Sweden.

Design: Prospective case series.

Methods: All cataract surgery cases during a 1-year period were included. The study group had the standard routine at the clinic, that is, no planned postoperative visit for patients without comorbidity and uneventful surgery. For the control group, patients who had surgery during 1 month of the 1-year period were chosen. All these patients had a planned postoperative visit. All surgeons involved were experienced. The outcome measures were any planned postoperative visit, any complication and/or adverse event, postoperative corrected distance visual acuity (CDVA), and any postoperative control/contact initiated by the patient.

Results: The study comprised 1249 patients (1115 in the study group and 134 in the control group). No significant differences in demographics, postoperative CDVA, frequency of planned visits because of ocular comorbidity, or postoperative patient-initiated contacts were found between the 2 groups. Of the 1249 patients, 9% (117 patients) initiated a postoperative contact, of whom 26% (30 patients) also had a scheduled visit. The reasons for the patient-initiated contacts were visual disturbance, redness and/or chafing, pain, and anxiety. An evaluation of all medidal records 2 years postoperatively found no reports of missed adverse events.

Conclusions: It was possible to refrain from planned,postoperafive visits for patients having uncomplicated cataract surgery. However, preoperatively, patients with comorbidities should be provided with individual planning of their postoperative follow-up. Preoperative counseling is important, and the clinic must have resources to answer questions from patients and be prepared for additional unplanned postoperative visits.

Place, publisher, year, edition, pages
Elsevier, 2017
National Category
Ophthalmology Surgery
Identifiers
urn:nbn:se:umu:diva-142002 (URN)10.1016/j.jcrs.2017.06.042 (DOI)000413889000010 ()28991615 (PubMedID)
Available from: 2017-11-21 Created: 2017-11-21 Last updated: 2018-10-31Bibliographically approved
Westborg, I., Albrecht, S. & Rosso, A. (2017). Risk For Low Visual Acuity After 1 And 2 Years Of Treatment With Ranibizumab Or Bevacizumab For Patients With Neovascular Age-Related Macular Degeneration. Retina, 37(11), 2035-2046
Open this publication in new window or tab >>Risk For Low Visual Acuity After 1 And 2 Years Of Treatment With Ranibizumab Or Bevacizumab For Patients With Neovascular Age-Related Macular Degeneration
2017 (English)In: Retina, ISSN 0275-004X, E-ISSN 1539-2864, Vol. 37, no 11, p. 2035-2046Article in journal (Refereed) Published
Abstract [en]

Purpose: To investigate how patients with neovascular age-related macular degeneration treated with ranibizumab or bevacizumab respond to treatment in daily clinical practice.

Methods: Data from the Swedish Macula Register on the treatment received by 3,912 patients during 2011 to 2014 is reported. Patients' characteristics at the first visit, visual acuity, number of injections, and reason for terminating the treatment if applicable are discussed. Furthermore, the risk of having poor vision (visual acuity under 60 Early Treatment Diabetes Retinopathy Study letters or approximately 20/60 Snellen) is calculated for the treated eye after 1 year and 2 years.

Results: The treatment outcome depends on the visual acuity at the first visit. For patients with visual acuity more than 60 letters, the risk of having a visual acuity lower than 60 letters after 1 year or 2 years of treatment is approximately 20%. However, for patients with low visual acuity at diagnosis (fewer than 60 letters), the risk is approximately 60%. The risk of having a visual acuity lower than 60 letters does not depend on the choice of treatment drug.

Conclusion: Treatment with anti-vascular endothelial growth factor intravitreal injections mainly maintains the visual acuity level, and only approximately 20% and 40% of the patients required vision rehabilitation after 1 year and 2 years, respectively.

Place, publisher, year, edition, pages
Lippincott Williams & Wilkins, 2017
Keywords
neovascular age-related macular degeneration, bevacizumab, choroidal neovascularization, ETDRS, nibizumab, register data
National Category
Ophthalmology
Identifiers
urn:nbn:se:umu:diva-145623 (URN)10.1097/IAE.0000000000001431 (DOI)000425208800022 ()28141748 (PubMedID)
Available from: 2018-03-15 Created: 2018-03-15 Last updated: 2018-06-09Bibliographically approved
Westborg, I., Granstam, E., Rosso, A., Albrecht, S., Karlsson, N. & Lövestam-Adrian, M. (2017). Treatment for neovascular age-related macular degeneration in Sweden: outcomes at seven years in the Swedish Macula Register. Acta Ophthalmologica, 95(8), 787-795
Open this publication in new window or tab >>Treatment for neovascular age-related macular degeneration in Sweden: outcomes at seven years in the Swedish Macula Register
Show others...
2017 (English)In: Acta Ophthalmologica, ISSN 1755-375X, E-ISSN 1755-3768, Vol. 95, no 8, p. 787-795Article in journal (Refereed) Published
Abstract [en]

Purpose: To present Swedish Macula Register (SMR) data regarding treatment of neovascular age-related macular degeneration (AMD) in clinical practice since 2008.

Methods: A retrospective register-based study was conducted. Evaluation of baseline demographics, visual outcome and number of injections during this period is presented.

Results: Mean age at diagnosis was 79 ± (SD) 8 years; 65% were female. The proportion of patients with <2 months' duration of symptoms increased from 26% in 2008 to 41% in 2014 (p = 0.001). Mean visual acuity (VA) at baseline increased from 54.3 ± 15.0 early treatment diabetic retinopathy study (ETDRS) letters in 2008 to 57.8 ± 15.6 letters in 2014 (CI95 2.6; 4.3; p < 0.001). Mean VA after 1 year of treatment increased from 57.8 ± 17.7 ETDRS letters for patients who started the treatment in 2008 to 62.8 ± 16.4 ETDRS letters in patients starting treatment in 2014 (CI95 2.67; 4.64; p < 0.001). During all study years, the proportion of patients with an improvement in VA of between 5 and 15 letters was around 30%, while 14% had VA improvement of more than 15 letters. The mean number of injections during the first treatment year increased from 4.3 ± 1.9 in 2008 to 5.9 ± 2.9 in 2014 (CI95 1.40; 1.67; p < 0.001). Seven-year follow-up of 322 eyes showed a mean change of -1 letters from baseline, with a mean of 21 injections for the entire period.

Conclusion: The duration of symptoms before treatment decreased, while VA at baseline and after 1 year of treatment increased over the years and so did the number of injections. Long-term follow-up demonstrated stable VA.

Keywords
ETDRS, Swedish Macula Register, age-related macular degeneration, anti-VEGF, anti-vascular endothelial growth factor, neovascular AMD
National Category
Ophthalmology
Identifiers
urn:nbn:se:umu:diva-144034 (URN)10.1111/aos.13539 (DOI)000417645900022 ()28834299 (PubMedID)
Available from: 2018-01-18 Created: 2018-01-18 Last updated: 2018-06-09Bibliographically approved
Rodrigues, I. A., Sprinkhuizen, S. M., Barthelmes, D., Blumenkranz, M., Cheung, G., Haller, J., . . . Gillies, M. C. (2016). Defining a Minimum Set of Standardized Patient-centered Outcome Measures for Macular Degeneration. American Journal of Ophthalmology, 168, 1-12
Open this publication in new window or tab >>Defining a Minimum Set of Standardized Patient-centered Outcome Measures for Macular Degeneration
Show others...
2016 (English)In: American Journal of Ophthalmology, ISSN 0002-9394, E-ISSN 1879-1891, Vol. 168, p. 1-12Article in journal (Refereed) Published
Abstract [en]

PURPOSE: To define a minimum set of outcome measures for tracking, comparing, and improving macular degeneration care.

DESIGN: Recommendations from a working group of international experts in macular degeneration outcomes registry development and patient advocates, facilitated by the International Consortium for Health Outcomes Measurement (ICHOM).

METHODS: Modified Delphi technique, supported by structured teleconferences, followed by online surveys to drive consensus decisions. Potential outcomes were identified through literature review of outcomes collected in existing registries and reported in major clinical trials. Outcomes were refined by the working group and selected based on impact on patients, relationship to good clinical care, and feasibility of measurement in routine clinical practice.

National Category
Ophthalmology
Identifiers
urn:nbn:se:umu:diva-126624 (URN)10.1016/j.ajo.2016.04.012 (DOI)000381166600001 ()27131774 (PubMedID)
Available from: 2016-11-22 Created: 2016-10-12 Last updated: 2018-06-09Bibliographically approved
Granstam, E., Westborg, I., Barkander, A., Börjesson, M., Lindahl, S., Meszaros, E., . . . Lövestam-Adrian, M. (2016). Reduced occurrence of severe visual impairment after introduction of anti-Vascular Endothelial Growth Factor in wet age-related macular degeneration: a population- and register-based study from northern Sweden. Acta Ophthalmologica, 94(7), 646-651
Open this publication in new window or tab >>Reduced occurrence of severe visual impairment after introduction of anti-Vascular Endothelial Growth Factor in wet age-related macular degeneration: a population- and register-based study from northern Sweden
Show others...
2016 (English)In: Acta Ophthalmologica, ISSN 1755-375X, E-ISSN 1755-3768, Vol. 94, no 7, p. 646-651Article in journal (Refereed) Published
Abstract [en]

Purpose To study the occurrence of severe visual impairment (SVI) and treatment outcome at 12months in patients treated for wet age-related macular degeneration (AMD) by use of data from the Swedish Macula Register (SMR) and referrals to the regional low vision clinics in five northern counties.

Methods Referrals to low vision clinics during 2005, 2009 and 2013 and treatment outcome at 12months from the SMR database from 2008 until 2013 in patients >65years of age in five northern counties were included in the survey.

Results The rate of referral due to AMD was significantly reduced during the time period (-48%; p<0.001). At 12months, a significant slight mean improvement in logMAR visual acuity (VA) was observed (-0.01, SD 0.37; p<0.001) after a mean of 5.02.3 anti-vascular endothelial growth factor (VEGF)-injections were administered. Age and low baseline VA was associated with less favourable visual outcome (p<0.001).

Conclusion Referral rate to low vision clinic is a valuable tool for estimating occurrence of SVI and fell between the years 2005 until 2013. Data from the SMR showed improvement in visual acuity on the whole, but also identified patients at high risk for developing SVI during anti-VEGF-treatment.

Keywords
anti-vascular endothelial growth factor, low vision clinics, Swedish Macula Register, wet AMD
National Category
Ophthalmology
Identifiers
urn:nbn:se:umu:diva-129929 (URN)10.1111/aos.13187 (DOI)000386631400021 ()27545047 (PubMedID)
Available from: 2017-01-11 Created: 2017-01-10 Last updated: 2018-06-09Bibliographically approved
Westborg, I. & Mönestam, E.Optimizing follow-up after cataract surgery: comparison of two institutions.
Open this publication in new window or tab >>Optimizing follow-up after cataract surgery: comparison of two institutions
(English)Manuscript (preprint) (Other academic)
National Category
Ophthalmology
Identifiers
urn:nbn:se:umu:diva-152956 (URN)
Available from: 2018-10-31 Created: 2018-10-31 Last updated: 2018-10-31
Organisations

Search in DiVA

Show all publications